Importantly, YTHDC1-directed RBM4 splicing is governed by AURKA accumulated in the nucleus of cancer cells, therefore targeting AURKA with its nuclear translocation inhibitors effectively suppresses the oncogenic switch of RBM4 and tumor progression. The gene discussed is RBM4; the disease is neoplasm.